Developer docs
API playgroundTry for free, no card

Search company profiles

Embecta

Full company profile

uuid0006q7n

Namestring
Embecta
Legal namestring
Embecta Corp.
Websiteurl
embecta.com
Company typeenum
Public
Founded yearint
2022
Descriptiontext

Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company headquartered in Parsippany, NJ, that operates a global portfolio of injection and drug delivery devices built around a 100-year legacy in insulin delivery inherited from its 2022 spinoff from Becton Dickinson. The core product line consists of pen needles (Nano 2nd Gen, Nano 4mm, and the Ultra-Fine portfolio) and Ultra-Fine insulin syringes, supplemented by accessories such as alcohol swabs. The company historically derived over 70% of revenue from pen needles and serves more than 30 million people across 100+ countries through healthcare providers, pharmacies, and a direct-to-consumer e-commerce storefront.

Embecta's business model is primarily a hardware sales / medical device model: products are sold through healthcare provider channels, global distributor networks, and retail pharmacy partnerships, with pricing not publicly disclosed and revenue collected via standard medical device reimbursement and pharmacy channels. Following the May 2026 acquisition of UK-based Owen Mumford Holdings Limited (up to £150M including earnout tied to Aidaptus sales through June 2029), the portfolio expanded to include the Aidaptus auto-injector platform — a two-step, single-use device accommodating both 1-mL and 2.25-mL prefilled glass syringes in a single base unit. A March 2026 distribution partnership with NanoTess added the NanoSALV Catalytic wound care gel across 14,000+ Canadian pharmacies, marking the company's first wound care product distribution in Canada and extending the addressable market beyond pure injection devices into adjacent diabetic wound care.

Operationally, the company employs approximately 2,000 people globally and is undergoing a defensive strategic pivot following material deterioration in its core franchise: Q2 fiscal 2026 revenue declined 14.4% YoY to $221.8M with U.S. revenue down 29.4% on pen needle market share loss, full-year 2026 guidance was reduced to $1.015-$1.035B (from prior $1.071-$1.093B), the quarterly dividend was cut 93% from $0.15 to $0.01, and more than 15 securities class action lawsuits have been filed alleging concealment of U.S. pen needle competitive threats. Embecta has announced a review of cost structure and organizational footprint, while pursuing commercial leadership changes (including a new North America president) and offensive moves (Owen Mumford, NanoTess) intended to reposition the company from a diabetes-focused manufacturer into a broader chronic-care drug delivery platform spanning obesity, autoimmune disease, and anaphylaxis.

Short descriptiontext

Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company that designs and sells insulin pen needles, syringes, and drug delivery devices to people with diabetes and broader chronic care patients across more than 100 countries, with approximately 2,000 employees and a 100-year insulin delivery heritage.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1,001–5,000
akta.pro rankint
HeadquartersParsippany, United States
HQ citystring
Parsippany
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
diabetes care devices, insulin pen needles, insulin delivery systems, drug delivery devices, medical device manufacturing
Industry4 codes
PRIMARYHLAHAHAE
Insulin Pen Needles, Syringes & Infusion Sets (Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAK
Glucagon Rescue Delivery Devices (Auto-Injectors, Nasal)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRADAMAB
First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)
NAICS code3 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Diabetes Care Medical Devices
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

Revenue from sale of pen needles, insulin syringes, safety injection devices, and related diabetes care products

globenewswire.com
2Drug Delivery Technology
TypeHardware Sales
Description

Revenue from auto-injectors and drug delivery devices following Owen Mumford acquisition

pulse2.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components7 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Others
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 5 records shown
1Nano
Description

Pen needle product line including Nano 2nd Gen Pen Needles and Nano 4mm Pen Needle

embecta.com
+4 more records
Core offering1 text field

Embecta manufactures and commercializes physical medical devices for insulin delivery, headlined by its Nano and Ultra-Fine pen needles and Ultra-Fine insulin syringes, along with injection accessories such as alcohol swabs. Following the May 2026 acquisition of Owen Mumford, the portfolio expanded to include the Aidaptus auto-injector platform for chronic care applications, and a distribution partnership added NanoSALV catalytic wound care gel in Canada. Products reach more than 30 million people across 100+ countries via healthcare providers, pharmacies, distributors, and an owned e-commerce storefront.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Serving more than 30 million people in over 100 countries
Product overview1 text field

Embecta operates as a medical supplies company offering a unified portfolio of diabetes care products centered on insulin injection devices. The core product line includes pen needles (Nano™ 2nd Gen, Nano™ 4mm, and Ultra-Fine™ varieties) and insulin syringes (Ultra-Fine™ Insulin Syringes), supplemented by accessories such as Alcohol Swabs. Following the May 2026 acquisition of Owen Mumford Holdings Limited, the portfolio expanded to include the Aidaptus® auto-injector platform—a two-step, single-use device compatible with 1-mL and 2.25-mL prefilled glass syringes—targeting chronic care markets including obesity, diabetes, autoimmune diseases, and anaphylaxis. A distribution partnership with NanoTess added NanoSALV Catalytic wound care gel for the Canadian market. The company serves more than 30 million people across over 100 countries with approximately 2,000 employees globally, and is pursuing strategic transformation from an insulin delivery leader into a broader medical supplies platform.

Product and service7 records
1Nano 2nd Gen Pen Needles
CategoryPen needles
Description

Second-generation pen needles designed for insulin injection, representing Embecta's updated pen needle technology for people with diabetes.

2Nano 4mm Pen Needle
CategoryPen needles
Description

Ultra-thin 4mm pen needle designed to reduce injection pain and improve patient comfort during insulin administration.

3Ultra-Fine Pen Needles
CategoryPen needles
Description

Portfolio of pen needles engineered for comfortable and effective insulin delivery, featuring ultra-thin needle technology.

4Ultra-Fine Insulin Syringes
CategoryInsulin syringes
Description

Insulin syringes designed for accurate insulin measurement and injection, available in multiple needle lengths and barrel sizes to meet varying patient needs.

5Alcohol Swabs
CategoryInjection accessories
Description

Accessory product for injection preparation, designed to sanitize the injection site prior to insulin administration.

6Aidaptus Auto-Injector Platform
CategoryAuto-injector drug delivery devices
Description

A two-step, single-use auto-injector platform capable of accommodating both 1-mL and 2.25-mL prefilled glass syringes in the same base device, acquired via Owen Mumford and targeting chronic care therapy areas including obesity, autoimmune diseases, and anaphylaxis.

7NanoSALV Catalytic Wound Care Gel
CategoryWound care
Description

Wound care product distributed through a partnership with Calgary-based NanoTess, designed as an early intervention and remedial treatment for diabetic foot ulcers, venous leg ulcers, and hard-to-heal wounds.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-15
Description

Embecta acquired Owen Mumford Holdings Limited, a UK-based medical device and drug delivery technology manufacturer, for £100 million upfront plus up to £50 million in performance-based payments tied to Aidaptus auto-injector sales through June 2029. The acquisition accelerates Embecta's strategic transformation from a diabetes-focused company into a broader medical supplies company serving chronic care markets including obesity, diabetes, autoimmune diseases, and anaphylaxis. Founded in 1952 and headquartered in Oxfordshire, UK, Owen Mumford developed healthcare devices and drug delivery technologies for over 70 years.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major diabetes device player selling MiniMed insulin pumps and AID systems. A broad incumbent in the diabetes care technology ecosystem that competes with Embecta's insulin delivery consumables via pump substitution.

TypeBroad incumbent
Description

Global leader in insulin and GLP-1 therapies (Ozempic, Wegovy) whose pen delivery systems both drive and threaten Embecta's pen needle business. Operates broadly in diabetes care with overlapping device ecosystem influence.

TypeDirect peer
Description

Swiss manufacturer of pen needles, insulin injection systems, and auto-injectors (YpsoMate) serving diabetes and chronic care pharma—directly competitive with Embecta's pen needle and Aidaptus auto-injector portfolios.

TypeDirect peer
Description

Italy-based drug delivery device manufacturer offering pen injectors, auto-injectors, and prefilled syringe systems to global pharma—competing head-to-head with Embecta's newly acquired Owen Mumford capabilities.

TypeDirect peer
Description

Global leader in primary packaging and drug delivery components, including auto-injector platforms (SmartDose) and injectable components for insulin and GLP-1 therapies—a peer in the device platform space Embecta targets via Aidaptus.

TypeDirect peer
Description

Designer and manufacturer of insulin pumps and automated insulin delivery (AID) systems integrating with CGMs—directly competitive with Embecta's pen needle franchise as insulin delivery shifts toward automated systems.

TypeDirect peer
Description

Leading independent developer and manufacturer of auto-injectors used by pharma sponsors for chronic care biologics—directly overlapping with Embecta's Aidaptus platform and drug delivery ambitions post-Owen Mumford.

TypeDirect peer
Description

Maker of the Omnipod tubeless insulin pump, which competes for the same diabetes patients whose insulin delivery Embecta's pen needles serve. Insulet is a key substitute product driving Embecta's recent pen needle share loss.

TypeDirect peer
Description

Embecta's former parent and original developer of its diabetes care portfolio. BD retains adjacent injection and drug delivery businesses and continues to operate in the insulin delivery consumables category, making it the closest historical and product-line peer.

TypeEmerging player
Description

German medical device and infusion technology company with pen needles, syringes, and infusion sets overlapping Embecta's product portfolio. An emerging direct competitor in selected diabetes consumables and adjacent injection segments.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks7 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Embecta

Diabetes Care Medical Devicesembecta.com

Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company that designs and sells insulin pen needles, syringes, and drug delivery devices to people with diabetes and broader chronic care patients across more than 100 countries, with approximately 2,000 employees and a 100-year insulin delivery heritage.

What Embecta does

Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company headquartered in Parsippany, NJ, that operates a global portfolio of injection and drug delivery devices built around a 100-year legacy in insulin delivery inherited from its 2022 spinoff from Becton Dickinson. The core product line consists of pen needles (Nano 2nd Gen, Nano 4mm, and the Ultra-Fine portfolio) and Ultra-Fine insulin syringes, supplemented by accessories such as alcohol swabs. The company historically derived over 70% of revenue from pen needles and serves more than 30 million people across 100+ countries through healthcare providers, pharmacies, and a direct-to-consumer e-commerce storefront.

Embecta's business model is primarily a hardware sales / medical device model: products are sold through healthcare provider channels, global distributor networks, and retail pharmacy partnerships, with pricing not publicly disclosed and revenue collected via standard medical device reimbursement and pharmacy channels. Following the May 2026 acquisition of UK-based Owen Mumford Holdings Limited (up to £150M including earnout tied to Aidaptus sales through June 2029), the portfolio expanded to include the Aidaptus auto-injector platform — a two-step, single-use device accommodating both 1-mL and 2.25-mL prefilled glass syringes in a single base unit. A March 2026 distribution partnership with NanoTess added the NanoSALV Catalytic wound care gel across 14,000+ Canadian pharmacies, marking the company's first wound care product distribution in Canada and extending the addressable market beyond pure injection devices into adjacent diabetic wound care.

Operationally, the company employs approximately 2,000 people globally and is undergoing a defensive strategic pivot following material deterioration in its core franchise: Q2 fiscal 2026 revenue declined 14.4% YoY to $221.8M with U.S. revenue down 29.4% on pen needle market share loss, full-year 2026 guidance was reduced to $1.015-$1.035B (from prior $1.071-$1.093B), the quarterly dividend was cut 93% from $0.15 to $0.01, and more than 15 securities class action lawsuits have been filed alleging concealment of U.S. pen needle competitive threats. Embecta has announced a review of cost structure and organizational footprint, while pursuing commercial leadership changes (including a new North America president) and offensive moves (Owen Mumford, NanoTess) intended to reposition the company from a diabetes-focused manufacturer into a broader chronic-care drug delivery platform spanning obesity, autoimmune disease, and anaphylaxis.

Embecta firmographics

Firmographics
Name
Embecta
Legal name
Embecta Corp.
Website
https://embecta.com
Company type
Public
Founded year
2022
Operating status
Operating
Headcount range
1,001–5,000 employees
Short description
Embecta Corp. (NASDAQ: EMBC) is a publicly traded medical device company that designs and sells insulin pen needles, syringes, and drug delivery devices to people with diabetes and broader chronic care patients across more than 100 countries, with approximately 2,000 employees and a 100-year insulin delivery heritage.
Ownership category
akta.pro rank

Embecta industry classification

Industry
Product category
Diabetes Care Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)
SIC
Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAHAHAE
Insulin Pen Needles, Syringes & Infusion Sets (Consumables)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYHLAHAIAC
Pen Injectors (Insulin/GLP-1/Other Pens)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
SECONDARYHLAHAHAK
Glucagon Rescue Delivery Devices (Auto-Injectors, Nasal)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Diabetes Care Devices (CGM, Insulin Delivery)
SECONDARYCRADAMAB
First Aid & Wound Care (Bandages, Dressings, Antiseptics, Burn Care)
Consumer Products & Retail/Consumer Packaged Goods (CPG) Manufacturing & Brands/Health & Hygiene OTC Consumer Goods (First Aid, Oral Care, Personal Health)

Keywords

  • Diabetes care devices
  • Insulin pen needles
  • Insulin delivery systems
  • Drug delivery devices
  • Medical device manufacturing

Where Embecta is headquartered

Location

Headquarters

HQ city
Parsippany
HQ country
United States
HQ region
North America

Offices2 records

Markets served

Embecta business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Others

Revenue model

  1. Medical Device Sales: Revenue from sale of pen needles, insulin syringes, safety injection devices, and related diabetes care products
  2. Drug Delivery Technology: Revenue from auto-injectors and drug delivery devices following Owen Mumford acquisition

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Embecta product offering

Product offering

Core offering

Embecta manufactures and commercializes physical medical devices for insulin delivery, headlined by its Nano and Ultra-Fine pen needles and Ultra-Fine insulin syringes, along with injection accessories such as alcohol swabs. Following the May 2026 acquisition of Owen Mumford, the portfolio expanded to include the Aidaptus auto-injector platform for chronic care applications, and a distribution partnership added NanoSALV catalytic wound care gel in Canada. Products reach more than 30 million people across 100+ countries via healthcare providers, pharmacies, distributors, and an owned e-commerce storefront.

Product overview

Embecta operates as a medical supplies company offering a unified portfolio of diabetes care products centered on insulin injection devices. The core product line includes pen needles (Nano™ 2nd Gen, Nano™ 4mm, and Ultra-Fine™ varieties) and insulin syringes (Ultra-Fine™ Insulin Syringes), supplemented by accessories such as Alcohol Swabs. Following the May 2026 acquisition of Owen Mumford Holdings Limited, the portfolio expanded to include the Aidaptus® auto-injector platform—a two-step, single-use device compatible with 1-mL and 2.25-mL prefilled glass syringes—targeting chronic care markets including obesity, diabetes, autoimmune diseases, and anaphylaxis. A distribution partnership with NanoTess added NanoSALV Catalytic wound care gel for the Canadian market. The company serves more than 30 million people across over 100 countries with approximately 2,000 employees globally, and is pursuing strategic transformation from an insulin delivery leader into a broader medical supplies platform.

Differentiator

Problem solved

Functional benefit

Brands

  • Nano: Pen needle product line including Nano 2nd Gen Pen Needles and Nano 4mm Pen Needle
  • Ultra-Fine
  • Aidaptus
  • AutoShield Duo
  • NanoSALV

Products and services

  • Nano 2nd Gen Pen Needles Second-generation pen needles designed for insulin injection, representing Embecta's updated pen needle technology for people with diabetes.
  • Nano 4mm Pen Needle Ultra-thin 4mm pen needle designed to reduce injection pain and improve patient comfort during insulin administration.
  • Ultra-Fine Pen Needles Portfolio of pen needles engineered for comfortable and effective insulin delivery, featuring ultra-thin needle technology.
  • Ultra-Fine Insulin Syringes Insulin syringes designed for accurate insulin measurement and injection, available in multiple needle lengths and barrel sizes to meet varying patient needs.
  • Alcohol Swabs Accessory product for injection preparation, designed to sanitize the injection site prior to insulin administration.
  • Aidaptus Auto-Injector Platform A two-step, single-use auto-injector platform capable of accommodating both 1-mL and 2.25-mL prefilled glass syringes in the same base device, acquired via Owen Mumford and targeting chronic care therapy areas including obesity, autoimmune diseases, and anaphylaxis.
  • NanoSALV Catalytic Wound Care Gel Wound care product distributed through a partnership with Calgary-based NanoTess, designed as an early intervention and remedial treatment for diabetic foot ulcers, venous leg ulcers, and hard-to-heal wounds.

Quantifiable outcome

  • Serving more than 30 million people in over 100 countries

Companies that use Embecta

Customer profile

Named customers1 record

Segments4 records

Ideal customer profiles3 records

Embecta technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Embecta partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Owen Mumford Holdings LimitedcoreStrategic or Co-development Partner · 15 May 2026Embecta acquired Owen Mumford Holdings Limited, a UK-based medical device and drug delivery technology manufacturer, for £100 million upfront plus up to £50 million in performance-based payments tied to Aidaptus auto-injector sales through June 2029. The acquisition accelerates Embecta's strategic transformation from a diabetes-focused company into a broader medical supplies company serving chronic care markets including obesity, diabetes, autoimmune diseases, and anaphylaxis. Founded in 1952 and headquartered in Oxfordshire, UK, Owen Mumford developed healthcare devices and drug delivery technologies for over 70 years.

Scale indicators9 records

Recent moves6 records

Expansion highlights5 records

Embecta competitors and assessment

Company assessment

Broad incumbents

  • Medtronic (Diabetes division): Major diabetes device player selling MiniMed insulin pumps and AID systems. A broad incumbent in the diabetes care technology ecosystem that competes with Embecta's insulin delivery consumables via pump substitution.
  • Novo Nordisk: Global leader in insulin and GLP-1 therapies (Ozempic, Wegovy) whose pen delivery systems both drive and threaten Embecta's pen needle business. Operates broadly in diabetes care with overlapping device ecosystem influence.

Direct peers

  • Ypsomed: Swiss manufacturer of pen needles, insulin injection systems, and auto-injectors (YpsoMate) serving diabetes and chronic care pharma—directly competitive with Embecta's pen needle and Aidaptus auto-injector portfolios.
  • Stevanato Group: Italy-based drug delivery device manufacturer offering pen injectors, auto-injectors, and prefilled syringe systems to global pharma—competing head-to-head with Embecta's newly acquired Owen Mumford capabilities.
  • West Pharmaceutical Services: Global leader in primary packaging and drug delivery components, including auto-injector platforms (SmartDose) and injectable components for insulin and GLP-1 therapies—a peer in the device platform space Embecta targets via Aidaptus.
  • Tandem Diabetes Care: Designer and manufacturer of insulin pumps and automated insulin delivery (AID) systems integrating with CGMs—directly competitive with Embecta's pen needle franchise as insulin delivery shifts toward automated systems.
  • SHL Medical: Leading independent developer and manufacturer of auto-injectors used by pharma sponsors for chronic care biologics—directly overlapping with Embecta's Aidaptus platform and drug delivery ambitions post-Owen Mumford.
  • Insulet: Maker of the Omnipod tubeless insulin pump, which competes for the same diabetes patients whose insulin delivery Embecta's pen needles serve. Insulet is a key substitute product driving Embecta's recent pen needle share loss.
  • Becton Dickinson (BD): Embecta's former parent and original developer of its diabetes care portfolio. BD retains adjacent injection and drug delivery businesses and continues to operate in the insulin delivery consumables category, making it the closest historical and product-line peer.

Emerging players

  • B. Braun: German medical device and infusion technology company with pen needles, syringes, and infusion sets overlapping Embecta's product portfolio. An emerging direct competitor in selected diabetes consumables and adjacent injection segments.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks7 records

Key highlights6 records

Customer concentration

Embecta social profiles

Digital presence

Embecta financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Embecta leadership team

Management profile

Number of profiles

Profiles4 records

Embecta subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Embecta funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Embecta M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Embecta

What does Embecta do?

Embecta manufactures and commercializes physical medical devices for insulin delivery, headlined by its Nano and Ultra-Fine pen needles and Ultra-Fine insulin syringes, along with injection accessories such as alcohol swabs. Following the May 2026 acquisition of Owen Mumford, the portfolio expanded to include the Aidaptus auto-injector platform for chronic care applications, and a distribution partnership added NanoSALV catalytic wound care gel in Canada. Products reach more than 30 million people across 100+ countries via healthcare providers, pharmacies, distributors, and an owned e-commerce storefront.

Is Embecta a public or private company?

Embecta is a public company. It is classified as public and is currently operating.

When was Embecta founded?

Embecta was founded in 2022. It employs 1,001 to 5,000 people.

Where is Embecta based?

Embecta is headquartered in Parsippany, United States, in the North America region.

How does Embecta make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are drug Delivery Technology.

Who are Embecta's main competitors?

Broad incumbents on record are Medtronic (Diabetes division) and Novo Nordisk. Direct peers are Ypsomed, Stevanato Group, West Pharmaceutical Services, Tandem Diabetes Care, SHL Medical, Insulet and Becton Dickinson (BD). B. Braun is listed as an emerging player.

Does Embecta have an API?

No public API is recorded for Embecta.

What industry is Embecta in?

Embecta's product category is Diabetes Care Medical Devices. Its primary akta.pro industry code is HLAHAHAE, Insulin Pen Needles, Syringes & Infusion Sets (Consumables), with a secondary code of HLAHAIAC, Pen Injectors (Insulin/GLP-1/Other Pens). Its NAICS code is 339113 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
American Banking and Market NewsEmbecta Corp. (NASDAQ:EMBC) Stock Has Average Target Price of $11.00Embecta Corp. shares opened at $6.19 with a consensus 'Reduce' rating and an average price target of $11.00. The company reported Q2 EPS of $0.56, beating estimates, but revenue fell 8.1% year-over-year. Insiders bought 70,000 shares in the last 90 days, while institutional ownership stands at 93.83%.American Banking and Market NewsEmbecta Corp. $EMBC Shares Newly Purchased by Chicago Partners Investment Group LLCChicago Partners Investment Group acquired a new stake in Embecta Corp, buying 270,237 shares valued at about $1.81 million. Analysts have an average "Reduce" rating with a consensus target price of $11.00. The company reported Q2 EPS of $0.56, beating estimates, but revenue fell 8.1% year-over-year.Markets DailyIntegra LifeSciences (NASDAQ:IART) versus Embecta (NASDAQ:EMBC) Critical ReviewEmbecta and Integra LifeSciences are compared on valuation, profitability, and analyst ratings. Embecta trades at a lower P/E ratio and has a higher upside potential, while Integra LifeSciences beats on 8 of 14 factors. Analysts favor Embecta with a consensus price target of $11.00.MarketBeatEmbecta Corp. $EMBC Shares Acquired by CWA Asset Management Group LLCCWA Asset Management Group raised its Embecta stake by 43.4% in Q3, holding 537,838 shares. Insiders Devdatt Kurdikar and Jeffrey Z. Mann bought 30,000 and 20,000 shares respectively on August 12. Analysts rate the stock a Reduce with a $11 price target.YahooWhat Embecta Bears Saw Before A 55% DropEmbecta's shares fell 54.5% over the past year, with Q3 2026 revenue dropping to $271.7 million from $295.5 million and net margin halving from 15.4% to 7.8%. The decline reflects pressure on pen needles and GLP-1 partnerships, with the current price below the selected narrative's fair value.Markets DailyVenus Concept (NASDAQ:VERO) vs. Embecta (NASDAQ:EMBC) Head-To-Head ComparisonEmbecta outperforms Venus Concept on 12 of 13 factors, including revenue, earnings, and profitability. Embecta's consensus target price of $11.00 implies a 77.99% upside, while Venus Concept trades at a lower P/E ratio. Analysts favor Embecta as the more favorable investment.MarketBeatEmbecta Corp. (NASDAQ:EMBC) Stock Has Consensus Price Target of $11.00Analysts rate Embecta Corp. with a consensus 'Reduce' and a $11.00 price target. The company beat Q2 earnings estimates with $0.56 EPS and $271.70M revenue, though revenue fell 8.1% year-over-year. It also declared a $0.01 quarterly dividend and insiders made mixed stock purchases and sales.American Banking and Market NewsEmbecta Corp. (NASDAQ:EMBC) Stock Has Consensus Price Target of $11.00Embecta Corp. received a consensus "Reduce" rating from five analysts, with an average price target of $11.00. The stock opened at $6.18, and the company reported Q2 EPS of $0.56, beating estimates, though revenue fell 8.1% year-over-year. The firm also declared a quarterly dividend of $0.01 per share.American Banking and Market NewsHead to Head Review: Embecta (NASDAQ:EMBC) vs. Venus Concept (NASDAQ:VERO)Embecta and Venus Concept are compared across financial and analyst metrics, with Embecta winning on 12 of 13 factors. Embecta has higher revenue ($1.02B vs $58.88M) and a consensus target price of $11.00, implying 83.64% upside, while Venus Concept trades at a lower P/E ratio.Defense WorldSanara MedTech (NASDAQ:SMTI) and Embecta (NASDAQ:EMBC) Head-To-Head AnalysisEmbecta and Sanara MedTech are compared on profitability, valuation, and analyst ratings. Embecta has higher revenue and earnings, with a consensus target price of $11.00 versus Sanara's $35.00, and beats Sanara on 8 of 13 factors.